quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:47:00·44d
PRRelease
bioAffinity Technologies Inc. logo

bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic

BIAF· bioAffinity Technologies Inc.
Health Care
Original source

Companies

  • BIAF
    bioAffinity Technologies Inc.
    Health Care

Related

  • SEC9d
    bioAffinity Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
  • PR9d
    New Case Study: bioAffinity Technologies' CyPath® Lung Diagnostic Supports Physician's Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy
  • SEC16d
    bioAffinity Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
  • PR16d
    bioAffinity Technologies' CyPath® Lung to Be Featured at Cleveland Clinic Annual "Advances in Early Lung Cancer Detection" Symposium April 16
  • SEC22d
    bioAffinity Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
  • PR22d
    bioAffinity Technologies' CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026
  • SEC28d
    bioAffinity Technologies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
  • SEC29d
    bioAffinity Technologies Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022